Novo Nordisk chief financial officer Karsten Munk Knudsen said on Wednesday the company was aware of reports of 10 deaths and ...

Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 ...

In interviews with Reuters, eight U.S. obesity specialists at universities and large health systems described a different ...

The weight-loss drug users and doctors whom The Times spoke to for this ... As powerful anti-obesity drugs become more widely ...

These are just some of the ways in which analysts forecast that the new wave of incredibly effective weight-loss drugs, known ...

These drugs are collectively known as GLP-1 agonists because they mimic the body’s natural hormone GLP-1, which regulates ...

Weight loss from behavioral changes or medication can improve glycemic control and increase menstrual frequency in polycystic ...

Nov. 6, 2024 – The FDA has updated the labels for all GLP-1 weight loss drugs with a warning about pulmonary aspiration ...

The Denmark-based drug maker Zealand Pharma said Tuesday that its experimental weight-loss drug could help patients lose ...

The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a ...

An injection pen of Zepbound, Eli Lilly’s weight-loss drug, is displayed in New York City, December 11, 2023. [Photo: Brendan ...

Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) ...